| No. (%) | |||||
---|---|---|---|---|---|---|
ECE | GCE | SBCE | CCE | After PCE | Overall | |
Total | ||||||
 Included studies | 26 | 15 | 303 | 43 | 15 | 402 |
 Patient, n | 2469 | 5197 | 91,069 | 5918 | 2624 | 107,277 |
 VCE, n | 2473 | 5197 | 91,872 | 5963 | 2574 | 108,079 |
Study characteristics | ||||||
 Midpoint of study period, mean (range) | 2008 (2005–2012) | 2014 (2004–2017) | 2008 (2001–2018) | 2012 (2006–2017) | 2011 (2006–2015) | 2009 (2001–2018) |
 Study design | ||||||
  RCT | 3 | 1 | 32 | 6 | 0 | 42 |
  Prospective | 23 | 11 | 81 | 34 | 7 | 156 |
  Retrospective | 0 | 3 | 190 | 3 | 8 | 204 |
 Region | ||||||
  Europe | 12 | 4 | 122 | 28 | 6 | 172 |
  North America | 11 | 0 | 64 | 3 | 1 | 79 |
  Asia | 2 | 11 | 105 | 11 | 7 | 136 |
  Oceania | 1 | 0 | 7 | 0 | 0 | 8 |
  Latin America | 0 | 0 | 3 | 0 | 0 | 3 |
  Africa | 0 | 0 | 1 | 0 | 0 | 1 |
  Multiple | 0 | 0 | 1 | 1 | 1 | 3 |
Patient characteristics | ||||||
 Mean age, y | 55.03 | 48.46 | 53.14 | 55.21 | 33.33 | 52.56 |
 Male sex, % | 65.89 | 57.31 | 51.16 | 52.47 | 51.86 | 52.51 |
 Patient groups | ||||||
  Population-based | 23 | 13 | 155 | 37 | 6 | 234 |
  Known IBD | 0 | 0 | 23 | 3 | 7 | 33 |
  OGIB | 2 | 2 | 91 | 1 | 0 | 96 |
  Abdominal pain or diarrhea | 0 | 0 | 8 | 0 | 0 | 8 |
  Suspected IBD | 0 | 0 | 9 | 0 | 0 | 9 |
  NSAIDs users | 0 | 0 | 8 | 0 | 0 | 8 |
  Mixed high-risk group | 0 | 0 | 6 | 0 | 2 | 8 |
  Suspected tumor | 1 | 0 | 3 | 2 | 0 | 6 |